1 / 5

22 Q Now, did any -- did any of the -- in light

22 Q Now, did any -- did any of the -- in light 1 of the cross-examination you had, has your opinion 2 regarding the labeling of the drug changed in any way 3 in terms of its adequacy and warning of risks and 4 benefits?

jael
Download Presentation

22 Q Now, did any -- did any of the -- in light

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 22 Q Now, did any -- did any of the -- in light 1 of the cross-examination you had, has your opinion 2 regarding the labeling of the drug changed in any way 3 in terms of its adequacy and warning of risks and 4 benefits? 5 A Not in the slightest. To me, it's a 6 success story. It doesn't always work that well, but 7 it was a signal, the signal was followed up on, the 8 signal was confirmed, the label was changed, the 9 recommendations were made to the doctors. 10 Unfortunately, doctors didn't change their 11 practice as much as they could have. David Graham 12 has confirmed that. Alternative drugs came out and 13 so the drug became obsolete and was removed from the 14 market. Everything worked right. It's the way the 15system should work, and to me, this is a model case.

  2. “Dear Patient Letter” • Clear statement of change in safety profile included with prescription refill • Highlighted for easy identification • Indication of newly approved status

More Related